Overview

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in patients that have previously failed to respond to treatment with peginterferon and ribavirin.
Phase:
Phase 2
Details
Lead Sponsor:
Romark Laboratories L.C.
Treatments:
Interferon-alpha
Nitazoxanide
Peginterferon alfa-2a
Ribavirin